Why Spectrum Shares Got Spanked

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of pharmaceutical company Spectrum Pharmaceuticals (NASDAQ: SPPI  ) plummeted 36% today after issuing a full-year revenue outlook that disappointed Wall Street.

So what: Spectrum that said that 2013 sales of its chemotherapy side-effect drug Fusilev will be in the range of only $80 million-$90 million (representing a whopping 56% decline from 2012), forcing analysts to drastically recalibrate their valuation estimates. While demand from doctors remains stable, management admitted that hospitals are certainly shifting to generics, reinforcing serious concerns over Fusilev's peak sales potential.

Now what: Management now sees 2013 total revenue of $160 million-$180 million, down about a third from 2012 and well below Wall Street's view of $297 million.

"The Company believes the majority of the impact from the change in ordering patterns will be reflected in the first half of 2013 and expects to return to a run-rate that more closely aligns with end-user demand by the end of the year," Spectrum reassured investors in a statement.

So while the stock remains a bit too speculative for conservative Fools, today's pullback might be a tasty opportunity for less risk-averse, short-term-oriented contrarians.

If you're interested in bigger-picture macro trends, Warren Buffett referred to one as "the tapeworm that's eating at American competitiveness." Find out what it is in our free report: "What's Really Eating At America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2310534, ~/Articles/ArticleHandler.aspx, 9/30/2016 7:46:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:00 PM
SPPI $4.58 Down -0.15 -3.17%
Spectrum Pharmaceu… CAPS Rating: ***